Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Darzalex Faspro, Kyprolis, and Dexamethasone a New Combination Approved for Multiple Myeloma

December 2021 Vol 7 No 6

On November 30, 2021, the FDA approved the combination of subcutaneous Darzalex Faspro (daratumumab and hyaluronidase-fihj; from Janssen Biotech) plus Kyprolis (carfilzomib; from Amgen) and dexamethasone for the treatment of adults with relapsed (coming back) or refractory (not responding to therapy) multiple myeloma who have received 1 to 3 previous lines of therapy.

This approval was based on a single-arm cohort in a multicohort, open-label clinical trial of 66 patients with relapsed or refractory multiple myeloma who received 1 or more previous lines of therapy.

All patients received the combination of Darzalex Faspro, Kyprolis, and dexamethasone.

The overall response rate was 84.8% with this combination. At an average follow-up of 9.2 months, the average duration of response to the combination had not been reached (meaning many patients were still responding). An estimated 85.2% of the patients maintained their response for 6 months or longer, and 82.5% of the patients maintained their response for 9 months or longer.

The most common side effects with this combination were upper respiratory tract infection, fatigue, insomnia, hypertension, diarrhea, cough, dyspnea, headache, pyrexia, nausea, and peripheral edema.

Recommended For You